Trend S, Jones AP, Cha L, Byrne SN, Geldenhuys S, Fabis-Pedrini MJ, Carrol WM, Cole JM, Booth DR, Lucas RM, Kermode AG, French MA, Hart PH. Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome. Front. Immunol. 9:1590. doi: 10.3389/fimmu.2018.01590

The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis. Fewings NL, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR. Journal of Autoimmunity. 2017 Jan 4. pii: S0896-8411(16)30284-0. doi: 10.1016/j.jaut.2016.12.006.

Fabry heterozygote mimicking multiple sclerosis. Marzena Fabis-Pedrini, Allan G Kermode. BMJ Case Reports (2017) DOI: 10.1136/bcr-2017-220274

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR. Data in Brief. (2017) Feb 21;11:364-370. DOI: 10.1016/j.dib.2017.02.040

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand’Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group. Mult Scler. 2017. Aug 1:1352458517728812. doi: 10.1177/1352458517728812

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, Lechner-Scott J, Slee M, Taylor BV, Vandenbroeck K, Comabella M, Martinelli F, Boneschi MD, The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), King C. Response to Interferon Beta Treatment in Multiple Sclerosis patients – A Genomewide Association Study. Pharmacogenomics J. 2016 Mar 22. doi: 10.1038/tpj.2016.20.

Acute reversible seronegative cerebellar ataxia in a young woman with ovarian teratoma. Yau WY, Fabis-Pedrini MJ, Kermode AG. J Neurol Sci. 2016 Oct 15;369:227-8. doi: 10.1016/j.jns.2016.08.033. Epub 2016 Aug 16

Binder MD, Fox AD, Merlo D, Johnson LJ, Giuffrida L, Calvert S, Akkermann R, Ma GZM, Perera AA, Gresle MM, Laverick L, Foo G, Fabis-Pedrini MJ, Spelman T, Jordan MA, Baxter AG, Foote S, Butzkueven H, Kilpatrick TJ, Field J. Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*1501 status. PLoS Genet. 2016 Mar 18;12(3):e1005853. doi: 10.1371/journal.pgen.1005853.

Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*1501 status. Binder MD, Fox AD, Merlo D, Johnson LJ, Giuffrida L, Calvert SE, Akkermann R, Ma GZ; *ANZgene., Perera AA, Gresle MM, Laverick L, Foo G, Fabis-Pedrini MJ, Spelman T, Jordan MA, Baxter AG, Foote S, Butzkueven H, Kilpatrick TJ, Field J. PLoS Genet. 2016 Mar 18;12(3):e1005853. doi: 10.1371/journal.pgen.1005853 (Kermode AG & Carroll WM are members of ANZgene Consortium)

McKay FC, Gatt PN, Fewings N, Parnell GP, Schibeci SD, Basuki MAI, Powell J, Fabis-Pedrini MJ, Kermode AG, Burke T, Vucic S, Stewart GJ, Booth DR. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. Clin Immunol. 2016 Jan 4. pii: S1521-6616(15)30084-X. doi: 10.1016/j.clim.2015.12.015.